Gene · 58508
Papers4,204
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 4,204
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases. | Cancer Cell Int | 2022 | 36371186 | PubTator, text mining | PubMed |
| Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. | Int J Mol Sci | 2022 | 36362398 | PubTator, text mining | PubMed |
| Clinical and Genetic Characteristics of a Cohort with Distal Vaginal Atresia. | Int J Mol Sci | 2022 | 36361644 | PubTator, text mining | PubMed |
| Prenatal Genetic Testing in the Era of Next Generation Sequencing: A One-Center Canadian Experience. | Genes (Basel) | 2022 | 36360262 | PubTator, text mining | PubMed |
| Estimating the Prevalence of De Novo Monogenic Neurodevelopmental Disorders from Large Cohort Studies. | Biomedicines | 2022 | 36359385 | PubTator, text mining | PubMed |
| Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives. | Cancers (Basel) | 2022 | 36358791 | PubTator, text mining | PubMed |
| Pathologies of Precursor Lesions of Biliary Tract Carcinoma. | Cancers (Basel) | 2022 | 36358777 | PubTator, text mining | PubMed |
| K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. | Cancers (Basel) | 2022 | 36358741 | PubTator, text mining | PubMed |
| CircRNA-Based Cervical Cancer Prognosis Model, Immunological Validation and Drug Prediction. | Curr Oncol | 2022 | 36354693 | PubTator, text mining | PubMed |
| The Neuroepigenetic Landscape of Vertebrate and Invertebrate Models of Neurodegenerative Diseases. | Epigenet Insights | 2022 | 36353727 | PubTator, text mining | PubMed |
| Epigenetic-Mediated Regulation of Gene Expression for Biological Control and Cancer: Cell and Tissue Structure, Function, and Phenotype. | Results Probl Cell Differ | 2022 | 36348114 | PubTator, text mining | PubMed |
A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy. | Investig Clin Urol | 2022 | 36347549 | PubTator, text mining | PubMed |
| Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study. | Ther Adv Med Oncol | 2022 | 36339926 | PubTator, text mining | PubMed |
| Molecular subtypes based on cuproptosis regulators and immune infiltration in kidney renal clear cell carcinoma. | Front Genet | 2022 | 36338990 | PubTator, text mining | PubMed |
| Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models. | Front Oncol | 2022 | 36338758 | PubTator, text mining | PubMed |
| Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. | Explor Target Antitumor Ther | 2022 | 36338524 | PubTator, text mining | PubMed |
| Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China. | BMC Med Genomics | 2022 | 36333792 | PubTator, text mining | PubMed |
| Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. | Nat Commun | 2022 | 36333289 | PubTator, text mining | PubMed |
| Acinic cell carcinoma of the breast: A comprehensive review. | Breast | 2022 | 36332545 | PubTator, text mining | PubMed |
| Metabolomic, Lipidomic, Transcriptomic, and Metagenomic Analyses in Mice Exposed to PFOS and Fed Soluble and Insoluble Dietary Fibers. | Environ Health Perspect | 2022 | 36331819 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/58508/papers?page=49